{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.7","upperLimit":"26.4","value":"22.9"},{"groupId":"OG001","lowerLimit":"11.0","upperLimit":"16.5","value":"13.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"628"},{"groupId":"OG001","value":"625"}],"units":"Participants"}],"description":"Participants achieved an objective response if they had a best overall response of partial response (PR) or complete response (CR). According to RECIST v1.1, PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter; CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \\<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels \\[if tumor markers were initially above the upper limit of normal (ULN)\\]. The percentage of participants who achieved an objective response=(number of participants with CR or PR)/(number of participants assessed)\\*100.","dispersionType":"95% Confidence Interval","groups":[{"description":"On Day 1 of each 21-day cycle, participants received ramucirumab DP followed by docetaxel. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\n* Ramucirumab DP: 10 mg/kg administered intravenously.\n* Docetaxel: 75 mg/m\\^2 (60 mg/m\\^2 for the countries of Korea and Taiwan only, with protocol amendment dated 22 May 2012) administered intravenously.","id":"OG000","title":"Ramucirumab and Docetaxel"},{"description":"On Day 1 of each 21-day cycle, participants received placebo followed by docetaxel. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\n* Placebo (matching Ramucirumab DP): 10 mg/kg administered intravenously.\n* Docetaxel: 75 mg/m\\^2 (60 mg/m\\^2 for the countries of Korea and Taiwan only, with protocol amendment dated 22 May 2012) administered intravenously.","id":"OG001","title":"Placebo and Docetaxel"}],"paramType":"NUMBER","populationDescription":"ITT population: All randomized participants grouped according to their assigned treatment at randomization.","reportingStatus":"POSTED","timeFrame":"Baseline to measured PD (up to 29 months)","title":"Percentage of Participants Achieving an Objective Response (Objective Response Rate)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}